• Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
Contact Icon Contact Icon Contact Icon
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact

Education Posts

Group PH: Global Health Issues

Article Type: Global Burden of Disease

Pulmonary Hypertension: From An Orphan Disease To A Global Epidemic

This review from a leader in the global aspects of pulmonary hypertension describes how what has been considered a rare disease, pulmonary hypertension, is actually quite common when one looks beyond the Western Countries and considers low-middle income countries.

Citation
Butrous G. Pulmonary hypertension: From an orphan disease to a global epidemic. Glob Cardiol Sci Pract. 2020 Apr 30;2020(1):e202005.
Source: https://pubmed.ncbi.nlm.nih.gov/33150150/

Targeting Pulmonary Vascular Disease to Improve Global Health: Pulmonary Vascular Disease: The Global Perspective

This paper presents an argument for taking a global view of the problem of pulmonary vascular disease. Since pulmonary hypertension may be a marker for advanced cardiac and pulmonary diseases, it emphasizes the need to educate health care leaders to begin establishing regional centers of excellence so that a worldwide approach can be applied that will benefit all.

Citation
Rich S, Herskowitz A. Targeting pulmonary vascular disease to improve global health: pulmonary vascular disease: the global perspective. Chest. 2010 Jun;137(6 Suppl):1S-5S.
Source: https://pubmed.ncbi.nlm.nih.gov/20522574/

A Global View of Pulmonary Hypertension

This is one of the more in-depth reviews of the global burden of pulmonary hypertension. They estimate a prevalence of 1% of the world population having pulmonary hypertension from any cause. They also estimate that the large majority of these patients (80%) live in developing countries, which emphasizes the challenge for both preventive and treatment strategies that will be affordable and accessible.

Citation
Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, Jing ZC, Gibbs JS. A global view of pulmonary hypertension. Lancet Respir Med. 2016 Apr;4(4):306-22.
Source: https://pubmed.ncbi.nlm.nih.gov/26975810/
Back Education Center
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Contact
    • Email

Tenax Therapeutics

A Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies.

Contact Icon Contact Icon Contact Icon

© Copyright 2025 Tenax Therapeutics. All Rights Reserved.
Site created by Top Shelf Design

  • Privacy Policy
  • Terms of Service